-
公开(公告)号：US20110160132A1
公开(公告)日：2011-06-30
申请号：US11996898
申请日：2006-07-28
CPC分类号： A61K38/1833 , A61K48/00 , A61K48/0016 , A61K48/0075 , C07K14/4753 , C12Q1/025 , G01N33/6872 , G01N2500/04
摘要： Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema.
摘要翻译： 这里描述的发现是HGF激活淋巴管内皮细胞的生长和迁移，从而促进淋巴管生成。 本发明是基于这一发现，并且提供了包含作为活性成分HGF或与其功能等同的蛋白质或化合物的淋巴管生成促进剂。 基于上述发现，本发明还提供了用于促进淋巴管生成的方法，其包括将淋巴水肿患者的HGF或与其功能等同的蛋白质局部给予受影响区域的步骤。
-
公开(公告)号：US20070281888A1
公开(公告)日：2007-12-06
申请号：US10593518
申请日：2005-03-17
IPC分类号： A61K38/18 , A61K31/7052 , A61P43/00 , A61P5/00 , C07H21/00 , C07K14/00 , C12N15/00 , C12N15/63 , C12N15/87 , C12N5/08
CPC分类号： C12N15/86 , A61K31/7088 , A61K38/00 , A61K48/00 , C07K14/515 , C07K14/52 , C12N2760/18643 , C12N2760/18671
摘要： It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and/or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and/or a pharmaceutical composition containing the polypeptide for treating a disease selected from the group consisting of obstructive arteriosclerosis, Buerger's disease, peripheral vascular disorder, angina, myocardial infraction, brain infarction, ischemic heart disease and ischemic brain disease; a method of treating these diseases; and an antibacterial composition. The above problems can be solved by isolating a novel peptide having the above-described activities and a nucleotide encoding this peptide.
摘要翻译： 旨在提供具有生长血管内皮细胞活性的新型多肽，促进c-fos启动子转录的活性，促进VEGF启动子的转录活性和/或血管生成活性的活性; 编码该多肽的多核苷酸; 上述多肽和/或含有治疗选自以下的疾病多肽的药物组合物：阻塞性动脉硬化，Buerger氏病，外周血管病症，心绞痛，心肌梗死，脑梗塞，缺血性心脏病和缺血性脑病; 一种治疗这些疾病的方法; 和抗菌组合物。 通过分离具有上述活性的新肽和编码该肽的核苷酸可以解决上述问题。
-
公开(公告)号：US07807176B2
公开(公告)日：2010-10-05
申请号：US10593518
申请日：2005-03-17
CPC分类号： C12N15/86 , A61K31/7088 , A61K38/00 , A61K48/00 , C07K14/515 , C07K14/52 , C12N2760/18643 , C12N2760/18671
摘要： It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and/or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and/or a pharmaceutical composition containing the polypeptide for treating a disease selected from the group consisting of obstructive arteriosclerosis, Buerger's disease, peripheral vascular disorder, angina, myocardial infraction, brain infarction, ischemic heart disease and ischemic brain disease; a method of treating these diseases; and an antibacterial composition. The above problems can be solved by isolating a novel peptide having the above-described activities and a nucleotide encoding this peptide.
摘要翻译： 旨在提供具有生长血管内皮细胞活性的新型多肽，促进c-fos启动子转录的活性，促进VEGF启动子的转录活性和/或血管生成活性的活性; 编码该多肽的多核苷酸; 上述多肽和/或含有治疗选自以下的疾病多肽的药物组合物：阻塞性动脉硬化，Buerger氏病，外周血管病症，心绞痛，心肌梗死，脑梗塞，缺血性心脏病和缺血性脑病; 治疗这些疾病的方法; 和抗菌组合物。 通过分离具有上述活性的新肽和编码该肽的核苷酸可以解决上述问题。
-
公开(公告)号：US09012417B2
公开(公告)日：2015-04-21
申请号：US10468717
申请日：2002-02-06
IPC分类号： A61K48/00 , A61K31/711 , A61K38/17 , C12N15/113
CPC分类号： A61K31/711 , A61K38/1709 , C12N15/113 , C12N2310/13
摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.
摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 所述至少一个诱饵可以选自NF-和kgr B诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自由NF-和κB诱饵，STAT-1诱饵，GATA-3诱饵 ，STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。
-
5.发明申请公开(公告)号：US20090105183A1
公开(公告)日：2009-04-23
申请号：US12314009
申请日：2008-12-02
IPC分类号： A61K31/7088 , A61P17/00
CPC分类号： A61K31/711 , A61K38/1709 , C12N15/113 , C12N2310/13
摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.
摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 所述至少一个诱饵可以选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵， STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。
-
公开(公告)号：US20090082263A1
公开(公告)日：2009-03-26
申请号：US11658897
申请日：2005-07-29
IPC分类号： A61K38/18 , A61K31/7088 , C07K14/475
CPC分类号： A61K38/1858 , A01K67/027 , A61K38/1825 , A61K38/1833 , A61K48/00
摘要： It is intended to provide a novel remedy for improving the brain function or preventing the same from worsening and a novel administration method for the remedy. Namely, a composition for preventing the brain function from worsening or improving the brain function which contains a cell growth factor. It is preferred that this cell growth factor is one selected from the group consisting of vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs) and hepatocyte growth factors (HGFs). A method for preventing the brain function from worsening or improving the brain function which comprises the step of administering a cell growth factor to a patient.
摘要翻译： 旨在提供改善脑功能或防止其相同恶化的新颖的治疗方法以及用于治疗的新型治疗方法。 即，用于防止脑功能恶化或改善包含细胞生长因子的脑功能的组合物。 优选该细胞生长因子是选自血管内皮生长因子（VEGF），成纤维细胞生长因子（FGF）和肝细胞生长因子（HGF））中的一种。 一种防止脑功能恶化或改善脑功能的方法，包括向患者施用细胞生长因子的步骤。
-
公开(公告)号：US07390482B2
公开(公告)日：2008-06-24
申请号：US10527195
申请日：2003-10-02
申请人： Yasufumi Kaneda , Kazuo Oshima , Ryuichi Morishita , Takeshi Kubo
发明人： Yasufumi Kaneda , Kazuo Oshima , Ryuichi Morishita , Takeshi Kubo
CPC分类号： C07K14/4753 , A61K38/1833 , A61K48/00 , A61K48/005 , C12N2799/021
摘要： The present invention provides a pharmaceutical preparation for hearing impairment, which is suitable for gene therapy of hearing impairment, that is, a pharmaceutical preparation for hearing impairment which comprises a virus envelope vector encapsulating a hepatocyte growth factor (HGF) gene or its plasmid as an active ingredient. Particularly, it is suitable as a pharmaceutical preparation for gene therapy for the purpose of prevention and treatment of deafness.
摘要翻译： 本发明提供一种适用于听力障碍的基因疗法的听力损伤药物制剂，即用于听觉障碍的药物制剂，其包含包封肝细胞生长因子（HGF）基因的病毒包膜载体或其质粒作为 有效成分。 特别地，作为用于预防和治疗耳聋的基因治疗的药物制剂是合适的。
-
8.发明授权Method of treating skin wounds with vectors encoding hepatocyte growth factor 有权用编码肝细胞生长因子的载体处理皮肤伤口的方法公开(公告)号：US07247620B2
公开(公告)日：2007-07-24
申请号：US10477166
申请日：2002-05-09
CPC分类号： A61K38/1709 , A61K38/1825 , A61K38/1833 , A61K38/1866 , A61K48/005
摘要： The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and hypoxia inducible factor (HIF)) as its active ingredient, and the administration of such an agent into the targeted skin diseases-affected area.
摘要翻译： 本发明涉及包含血管生成因子基因（如肝细胞生长因子（HGF），血管内皮生长因子（VEGF）），成纤维细胞生长因子（FGF）和缺氧诱导因子（HIF））的治疗性预防药物 活性成分，以及将这种药剂施用于目标皮肤疾病影响区域。
-
9.发明授权Method of treating skin ulcers with vectors encoding hepatocyte growth factor 有权用编码肝细胞生长因子的载体治疗皮肤溃疡的方法公开(公告)号：US07939504B2
公开(公告)日：2011-05-10
申请号：US11763361
申请日：2007-06-14
CPC分类号： A61K38/1709 , A61K38/1825 , A61K38/1833 , A61K38/1866 , A61K48/005
摘要： The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth f actor (FGF), and hypoxia inducible factor (HIF)) as its active ingredient, and the administration of such an agent into the targeted skin diseases-affected area.
摘要翻译： 本发明涉及包含血管生成因子基因（例如肝细胞生长因子（HGF），血管内皮生长因子（VEGF），成纤维细胞生长因子（FGF）和缺氧诱导因子（HIF））的治疗性预防药物 其活性成分，以及将这种药物施用于目标皮肤疾病影响区域。
-
10.发明申请METHOD OF TREATING SKIN WOUNDS WITH VECTORS ENCODING HEPATOCYTE GROWTH FACTOR 有权用编码肝细胞生长因子的向量处理皮肤伤口的方法公开(公告)号：US20070264321A1
公开(公告)日：2007-11-15
申请号：US11763361
申请日：2007-06-14
IPC分类号： A61K31/711 , A61K9/127 , A61P17/02 , C12N15/63
CPC分类号： A61K38/1709 , A61K38/1825 , A61K38/1833 , A61K38/1866 , A61K48/005
摘要： The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth f actor (FGF), and hypoxia inducible factor (HIF)) as its active ingredient, and the administration of such an agent into the targeted skin diseases-affected area.
摘要翻译： 本发明涉及包含血管生成因子基因（例如肝细胞生长因子（HGF），血管内皮生长因子（VEGF），成纤维细胞生长因子（FGF）和缺氧诱导因子（HIF））的治疗性预防药物 其活性成分，以及将这种药物施用于目标皮肤疾病影响区域。
-
-
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.023 秒)
